aTyr Pharma to Present Data for Inflammatory Myopathy and Interstitial Lung Disease at the 2012 American College of Rheumatology Annual Meeting

Detailed Characterization of Orphan Autoimmune Disease Provides Insight into Jo-1 Antibody Response

aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group

Dr. John Mendlein to Speak at Upcoming BIO International Convention

aTyr Pharma Appoints Dr. Alan Ezekowitz to Therapeutic Advisory Board

 Pioneer in Innate Immunity and Industry Expert to Help Guide  the Discovery and Development of Physiocrine-based Medicines

aTyr Pharma Expands Leadership Team to Advance New Breakthrough Medicines Based on Physiocrine Biology

 Dr. Jeffrey Greve Named Vice President, Research; Dr. Andrew Cubitt Named Vice President, Intellectual Property

aTyr Pharma Honored with Red Herring 100 North America Award for Discovering and Developing Innovative Medicines Based on Physiocrine Biology

Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics

Dr. Ashlock Named as Vice President, External Scientific Alliances and Human Genetics

aTyr Pharma Announces Formation of Therapeutic Advisory Board

Renowned Drug Hunters Assembled to Guide the Discovery of Innovative Protein Therapeutics Based on Physiocrine Pathways

aTyr Pharma Secures $23M Financing From Top Tier Venture Investor

Funding to Advance Highly Innovative Drugs Based on Recently Discovered Physiocrine Biology.

Dr. John Mendlein Joins aTyr Pharma as Executive Chairman

Serial Entrepreneur to Drive aTyr’s Pipeline of High Impact Medicines from a New Class of Naturally Occurring Human Proteins (Physiocrines)

aTyr announced today that John Mendlein, Ph. D., has joined their Board of Directors as Executive Chairman.

Pangu BioPharma, aTyr Pharma’s Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission

The Innovation and Technology Commission of the Hong Kong government has awarded Pangu BioPharma, the Hong Kong subsidiary of aTyr Pharma, a second grant to fund research it is performing in collaboration with the Hong Kong University of Science and Technology (HKUST).